Medinol’s ChampioNIR Peripheral DES Implanted in FIH Procedure

October 7, 2024—Medinol Ltd. announced the first-in-human (FIH) implantation of the ChampioNIR drug-eluting peripheral stent.

The procedure was performed by Professor Gerard S. Goh, MD, Head of Interventional Radiology, and Thodur Vasudevan, MD, Head of Vascular Surgery, at the Alfred Hospital in Melbourne, Australia.

According to the company, the ChampioNIR stent system features a hybrid mechanical design. Radial support is provided by the metallic component of the stent; longitudinal structure is provided by a bioresorbable polymeric mesh, providing flexibility and long-term durability in even the most challenging anatomies.

Additionally, a unique drug-elution paradigm releases drug from the entire cylindrical area of the stent, reducing diffusion distances and allowing therapeutic dosing of a large peripheral vessel with a limus drug for an extended period of time, stated Medinol.

“We were impressed with ChampioNIR’s deliverability and its straightforward deployment,” commented Prof. Goh in Medinol’s press release. “The frictionless deployment mechanism made the precise positioning of the stent very straightforward.”

Sahil Parikh, MD, added, “The ChampioNIR stent represents a breakthrough in treatment for superficial femoral artery lesions. I am excited to see this device come to life after years of development.”

Prof. Parikh is Principal Investigator of the CHAMPIONSHIP FIH study, which will enroll 30 patients at seven sites in Australia and the United States, advised the company.